RMAT´Â ½É°¢ÇÑ Áúȯ, ÀÇÇÐÀû ¹ÌÃæÁ· ¼ö¿äÀÇ Á¶°ÇÀ» °®Ãá Àç»ýÄ¡·áÁ¦¿¡ ÁöÁ¤
÷´Ü Àç»ýÀÇÇÐ Ä¡·áÁ¦´Â ½É°¢ÇÑ Áúȯ(Serious Condition)ÀÇ Ä¡·á, Á¶Àý, ¿ªÇà, ¿ÏÄ¡°¡ °¡´ÉÇϰí, ÀÇÇÐÀû ¹ÌÃæÁ· ¼ö¿ä(Unmet Medical Need)ÀÇ ÇØ°á °¡´É¼ºÀÌ ÀÖ´Â Àç»ýÄ¡·áÁ¦(Regenerative Medicine)ÀÇ °³¹ß°ú ½ÂÀÎÀ» ÃËÁøÇϱâ À§ÇÑ ÇÁ·Î±×·¥ÀÌ´Ù. Àç»ýÄ¡·áÁ¦ÀÇ ¹üÀ§¿¡´Â ¼¼Æ÷Ä¡·áÁ¦(Cell therapy), À¯ÀüÀÚÄ¡·áÁ¦(Gene therapy), Á¶Á÷°øÇÐ Ä¡·áÁ¦(Therapeutic tissue engineering product), ÀÎü¼¼Æ÷ ¹× Á¶Á÷ Á¦Ç°(Human cell and tissue product)µîÀÌ Æ÷ÇԵȴÙ. ½ÂÀÎ ½ÅûÀº IND Á¦ÃâºÎÅÍ End of Phase 2 Meeting ÀÌÀüÀÌ ÀÌ»óÀûÀÌ´Ù.
RMATÀÇ ÇýÅÃÀº ½Å¼Ó½É»ç ÇÁ·Î±×·¥ÀÇ ÇýÅÃÀÇ ´ëºÎºÐÀ» Æ÷ÇÔ
÷´Ü Àç»ýÀÇÇÐ Ä¡·áÁ¦ÀÇ ÇýÅÃÀº ¾Õ¿¡ ¾ð±ÞÇß´ø ÇÁ·Î±×·¥À» ÇÕÃijõ¾Ò´Ù°í ÇØµµ °ú¾ðÀÌ ¾Æ´Ò Á¤µµÀÌ´Ù. ¸ÕÀú 1)Çõ½ÅÀǾàǰ(Breakthrough Therapy)ÀÇ ¸ðµç ÇýÅÃÀ» Æ÷ÇÔÇϰí ÀÖÀ¸¸ç, 2) ÀÓ»óÀû ´ë¸®ÁöÇ¥(Surrogate Endpoints) ȤÀº Áß°£ÀÓ»ó ÁöÇ¥(Intermediate Clinical Endpoints)¿¡ ´ëÇÑ ÃæºÐÇÑ ÀÇ»ç¼ÒÅëÀ» ÅëÇÏ¿© 3)½Å¼Ó½É»ç(Accelerated Approval) ¹× ½ÂÀÎ ÈÄ ¿ä±¸»çÇ×(Post-approval requirements)¿¡ ´ëÇÑ Áö¿øÀ» Á¦°øÇÑ´Ù. ±×¸®°í 4)½ÂÀνÅû ½Ã ÀÓ»óµ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î ¿ì¼±½É»ç(Priority Review)ÀÇ ½ÅûÀÚ°ÝÀÌ ÁÖ¾îÁø´Ù.
RMAT ÇöÀç±îÁö ÃÑ 30°³ ÁöÁ¤µÇ¾úÀ¸¸ç ÁöÁ¤È®·üÀº 30ÆÛ¼¾Æ®
2016³â 12¿ùºÎÅÍ ½ÃÀÛÇÑ Ã·´Ü Àç»ýÀÇÇÐ Ä¡·áÁ¦ ÇÁ·Î±×·¥Àº 2017³â 31°³, 2018³â 47°³ ¾à¹°ÀÌ ½ÅûÇÏ¿´°í, 2019³â¿¡µµ 13°³ ǰ¸ñÀÌ ½ÅûµÇ¾ú´Ù. Áö±Ý±îÁö ÁöÁ¤µÈ ¾à¹°Àº 2017³â 11°³ 2018³â 18°³, 2019³â 1°³, ÃÑ 30°³·Î Áý°èµÈ´Ù. ÇöÀç±îÁö ÁöÁ¤È®·üÀº 30ÆÛ¼¾Æ® ¼öÁØÀ̸ç, ¼¼Æ÷Ä¡·áÁ¦ ¹× À¯ÀüÀÚÄ¡·áÁ¦ °³¹ß¾÷üÀÇ Áõ°¡¿Í ÇÔ²² ÷´Ü Àç»ýÀÇÇÐ Ä¡ ·áÁ¦·Î ÁöÁ¤µÇ´Â ¾à¹°ÀÇ ¼ýÀÚµµ ´Ã¾î³¯ °ÍÀ¸·Î Àü¸ÁÇÑ´Ù. Ãâó : ÇÑÈÅõÀÚÁõ±Ç ½ÅÀçÈÆ ¿¬±¸À§¿ø, Á¦¾à ¹ÙÀÌ¿À (Positive) FDA Series 1, ½Å¾à½ÂÀÎ ÇÁ·Î±×·¥( 2019.02.27)
|